002082SZSE
🚨 Material Event

Announcement Regarding the Subsidiary's Product, Huperzine A Injection, Winning the Bid in the Inter-provincial Alliance Procurement

✨ AI Summary

Wanbangde Pharmaceutical Holding Group announced that its subsidiary, Wanbangde Pharmaceutical Group, successfully won the bid for its Huperzine A Injection in an inter-provincial alliance centralized procurement led by Henan Province. The procurement cycle is two years, covering numerous provinces and regions across China. This win is expected to expand the product's market coverage in public hospitals and strengthen its market position in the treatment of cognitive impairment and myasthenia gravis.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Stock Code: 002082 Stock Abbreviation: ST Wanbang Announcement No.: 2026-061

Wanbangde Pharmaceutical Holding Group Co., Ltd.

Announcement Regarding the Subsidiary's Product, Huperzine A Injection, Winning the Bid in the Inter-provincial Alliance Procurement

Wanbangde Pharmaceutical Holding Group Co., Ltd. (hereinafter referred to as the "Company") and all members of its Board of Directors guarantee that the information disclosed is true, accurate, and complete, with no false records, misleading statements, or major omissions.

The Company's wholly-owned subsidiary, Wanbangde Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Wanbangde Pharmaceutical"), participated in the bidding for the centralized volume-based procurement of 34 types of drugs led by Henan Province. According to the "Announcement on the Inter-provincial Alliance Procurement of 34 Drugs (VIII)" issued by the "34-Drug Inter-provincial Alliance Procurement Office" on August 10, 2026, the Company's product, Huperzine A Injection, has won the bid in this procurement. The relevant details are announced as follows:

I. Basic Information of the Winning Product

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.